As India reported the lowest number of daily COVID-19 cases in four months, the government on Tuesday said a serosurvey has found that two-thirds of the population aged above six years has SARS-CoV-2 antibodies but stressed that around 40 crore people are still vulnerable to the infection and there is no room for complacency.
The overall seroprevalence was 67.6 per cent in the ICMR’s 4th national COVID serosurvey, held in June and July, that involved over 28,975 individuals (adults and children), apart from 7,252 healthcare workers, in 70 districts across 21 states where earlier three rounds were also conducted.
The seroprevalence in the age group of 6-9 years was 57.2 percent, in age group of 10-17 years was 61.6 percent, in 18-44 years was 66.7 percent, in 45-60 years was 77.6 percent and in over 60 years it was around 76.7 percent, the government said and attributed the rise to the role of delta variant in spreading the second wave and to the vaccination cover.
In the third serosurvey conducted in December-January, 2021, the sero-prevalence was 24.1 percent
Besides, 85 percent of the surveyed healthcare workers in the fourth round were found to have antibodies against SARS-CoV-2 and one-tenth of HCWs were still unvaccinated.
The government said the findings show there is a ray of hope, but there is no room for complacency and COVID-appropriate behaviour and community engagement have to be maintained.
According to the Union Health Ministry data updated on Tuesday, India recorded 30,093 new coronavirus infections, the lowest in 125 days, taking the total tally of COVID-19 cases to 3,11,74,322,
The death toll climbed to 4,14,482 with 374 daily fatalities, the lowest in 111 days, while the active cases have declined to 4,06,130, also the lowest in 117 days.
The active caseload comprises 1.30 percent of the total infections.
Over 42.15 crore vaccine doses have been provided to states and union territories (UTs) so far, through all sources.
Addressing a press conference, ICMR Director General Balram Bhargava said, “Two-thirds of the general population above the age of six, or 67.6 percent were found to have SARS-CoV-2 antibodies in the latest national serosurvey.
“A third of the population did not have SARS-CoV-2 antibodies, which means approximately 40 crore people are still vulnerable to COVID-19 infection,”
Those without antibodies run the risk of infection waves, Bhargava said.
More than half of the children (6-17 years) were seropositive and seroprevalence was similar in rural and urban areas, he informed.
Besides, 85 percent of the surveyed healthcare workers had antibodies against SARS-CoV-2 and one-tenth of HCWs were still unvaccinated.
The serosurvey was conducted over 28,975 individuals (adults and children), apart from 7,252 healthcare workers in 70 districts across 21 where earlier three rounds were also conducted.
In the serosurvey, there were 10 villages per ward from each district surveyed, 40 individuals per village or ward, 400 individuals aged 6 years and above per district and 100 healthcare workers per district from district and sub-district hospitals.
Amongst the adult population, there was no vaccine in 12,607 that is 62.2 percent while 24.8 percent or 5,038 people surveyed in the adult population had taken one dose of vaccination, while 13 percent or 2,631 individuals had both doses of vaccine.
In the general population, the total enrolled were 28,975 individuals that included 2,892 in the 6-9 years age group (10 percent), 5,799 in 10-17 (20 percent) and 20,284 those aged 18 years and above (70 percent).
“The overall seroprevalence in 67.6 per cent in the entire population that is 6 years and above.
“If you disaggregate this data, then between 6-9 years it was 57.2 percent, 10-17 it was 61.6 percent, 18-44 was 66.7 percent, 45-60 was 77.6 percent and over 60 years it was around 76.7 percent,” Bhargava said.
He also said that once India starts reopening schools, it will be wise to begin with the primary section as children have a lower number of ace receptors to which virus attaches, making them much better at handling viral infections than adults.
Among males (65.8 percent) and females (69.2 percent), there was not much difference.
The seroprevalence in rural areas was found to be 66.7 percent and slightly higher in urban at 69.6 percent.
As per vaccination status, it was seen in 62.3 percent among unvaccinated people, 81 percent among those who took single dose of vaccine while it was 89.8 percent in fully vaccinated people.
In the first serosurvey done in May-June 2020, the seroprevalence was 0.7 percent; in the second survey in August-September 2020, it was 7.1 percent; in the third serosurvey conducted in December-January, 2021 it was 24.1 percent.
“Overall seroprevalence in healthcare workers was 85.2 percent. We studied 7,252 healthcare workers and 10 percent had not taken the vaccine while 13.4 percent had taken one dose and 76.1 percent had taken both doses of vaccine,” he said,
An important point to remember here is that the national serosurvey is not a substitute for local (state or district) level survey, Bhargava said, adding it is just giving a bird’s eye view or a panoramic picture of what is happening in the nation.
But there is heterogeneity which is occurring from state to state, district to district and we should be cognisant of that, he said and informed that stat- led sentinel sero-surveillance will inform further state-level action.
“State heterogeneity indicates the possibility of future waves of infection. There might be some states where the population which is vulnerable is much higher there and so chances of future waves are higher in those states.
“Societal, public, religious and political congregations should be avoided. Non-essential travels should be discouraged and travel only if fully vaccinated,” he said.
NITI Aayog Member (Health ) Dr V K Paul said 40 crore people have no antibodies and the pandemic is in no way over.
The second wave is still persisting and the danger of new outbreaks is still very much there, he said.
“…that 40 crore people have no antibodies, we would like them to gain protection through vaccination and not the infection and that is the endeavour that this nation is mounting,” he said.
Because such a large pool of vulnerable population is still amongst us – one out of three – therefore the pandemic is in no way over,.. . the overall vulnerability for the nation still remains and that is very evident,” he said.
On the way forward, Bhargava highlighted the need to ensure full vaccination of all healthcare workers as soon as possible, accelerating vaccination coverage in vulnerable population groups and ensuring adherence to non-pharmaceutical interventions.
He also stressed on continued tracking of Covid-infection in SARI cases in district hospitals.
“That is another very important tool that we use the SARI (Severe acute respiratory infection patients) and test them for COVID and rule out if there is any sudden spike of COVID-19 in SARI patients. We need to identify clusters and clinical severity and INSACOG is tracking variants of concern,” he said.
Many states have done their own serosurveys and that will be very helpful in guiding the response to the pandemic.
Paul said the third serosurvey was in December-January, which may be taken as the seroprevalence post the end of the first wave and the rise in seropositivity that can be seen has two factors to it.
“One is the second wave that is the suffering that the delta variant inflicted on us but also part of seropositivity is coming from vaccination coverage and the gradient between vaccinated and unvaccinated can be seen,” he said.
On the situation in the country, Paul said Kerala is still “static to slight rise” and Maharashtra is seeing some decline.
Andhra Pradesh is still a cause of concern and 46 districts have more than 10 percent positivity, he said.
He said some states have more than 10 percent positivity. “It testifies to the fact that this level of seropositivity does not ensure that the pandemic is over and it is out there,” he warned.
On the vaccine shortage in some states, Paul said the states and UTS are informed two weeks in advance about the availability of the vaccines, so that they can plan accordingly.
In response to a question over the production of Covaxin by Bharat biotech, Paul said the company as part of their expansion had added Ankleshwar and Bangalore facilities apart from the Hyderabad facility.
“While the Ankleshwar plant is on track as per the schedule, the Bangalore facility faced some difficulties in the initial operationalisation due to which they had fallen little behind…but all issues have been resolved. The hitch has been sorted out and now they are on track.